Maintain JPM at neutral weight with $356-$360 tactical add trigger (25-50% tranche) and $345 stop; Q3 mid-October earnings is mandatory reassessment gate.
Hold JPM at neutral weight with $370 price target. The unanimous consensus across Research Manager, Trader, Conservative Analyst, and Neutral Analyst is binding over the lone Aggressive Analyst dissent. The 2:1 reward-to-risk math ($340 downside vs. $380-$400 upside) cited by the Aggressive Analyst is a conditional bet on imminent breakout that has failed for six sessions at $365.18—with MACD histogram at -0.36 (95% below June peak), declining volume (3-4M vs. 7-10M normal), and RSI making lower highs since mid-June, near-term risk-reward is approximately 1:1 to 1:2, not 2:1. The Neutral Analyst's $356-$360 zone offers measured re-engagement that neither buys at highs nor waits for the $340 ghost. Historical JPM window arithmetic (8/17 +1.3% alpha, 8/14 0.0%, 8/13 +0.1%, 8/12 -1.3%) confirms pre-earnings directional bets bleed alpha in both directions at this setup. Structural floor ($8.79B/quarter buybacks = 3.7% annualized of market cap, 50 SMA at $340.87, 200 SMA at $312.81) protects the position even in adverse scenarios. The $4.39B Q2 unusual item distorts comps but does not break the thesis—the underlying normalized run-rate of ~$6.30-$6.50 EPS (15-20% YoY growth) remains strong. The Aggressive Analyst correctly identifies franchise quality (17.8% ROE, $5T balance sheet, 34.92% net margins, $52B annualized capital return) but commits the category error of conflating franchise quality with entry-point attractiveness at 52-week highs. CEO succession and credit-cycle risks (net loans +36% to $1.52T) are real but warrant sizing constraint (neutral weight), not directional bet against the position.
| Position | Action |
|---|---|
| Price enters $356-$360 zone (Bollinger middle / 10 EMA / VWMA confluence) | Execute 25-50% of intended position as initial tranche |
| Price reaches structural floor at $340 | Full position deployment with $340 stop |
| Rating changes to Overweight | Do not mandate new hedge; retain existing December $340 puts as tail insurance |
| Pre-Q3 earnings with bearish technicals (not applicable to JPM at this setup) | Cross-ticker META/AVGO lessons do not force trim given 8-week catalyst horizon and intact uptrend above all MAs |
JPM is a best-in-class franchise compounding at 17.8% ROE in the most favorable macro regime for bank earnings in years—higher-for-longer rates driving NIM expansion while recession risk remains historically low—with a generational deal pipeline (Anthropic $10B+, ByteDance $30B+) and multi-year fee tailwinds from Gen Z premium card adoption, all at a fair multiple that doesn't price in the earnings beat trajectory.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $313.12 | bullish |
| 50 SMA | $340.87 | bullish |
| 10 EMA | $360.48 | bullish |
| RSI(14) | 64.45 | neutral |
| MACD | 6.66 | neutral |
| MACD Signal | 7.02 | bearish |
| MACD Histogram | -0.36 | bearish |
| Bollinger Middle (20 SMA) | $356.63 | neutral |
| Bollinger Upper Band | $367.94 | bullish |
| Bollinger Lower Band | $345.32 | bearish |
| ATR(14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price declines to $340 area (50 SMA at $340.87)
Then: Full deployment of intended position with $340 stop loss
Higher-for-longer rate environment is the single most favorable macro regime for JPM's NII franchise
↩ rebuts: “Bear's 'bond-rout' concern framing elevated rates as JPM-specific problem”
EV: +15-20% annually (double-leveraged upside from moderate multiple expansion + double-digit earnings growth)
JPM is priced for perfection at 14.5x forward P/E with a 1.77 PEG ratio, but faces eight major unpriced risks including credit cycle deterioration, CEO succession uncertainty, aggressive 26% annualized balance sheet growth, declining technical momentum, and increasingly difficult Q3/Q4 2026 earnings comps that will cause the stock to correct 10-15% when reality hits.
EV: -$34 to -$50 (13-17% downside from $363 to $313-$340) · concedes: The deal pipeline is real, though incremental revenue is measured in tens of millions per deal, not billions; Gen Z premium cards are a genuine multi-year tailwind, though already priced in after three years of consensus positivity; The unusual item was earnings, not accounting wizardry — but this distinction is irrelevant for valuation purposes since the market capitalizes normalized earnings, not peaks
→ vs conservative: Waiting for $350 entry is not risk management but leaving money on the table on a 17.8% ROE franchise with fortress balance sheet; the 50 SMA at $340.87 is a ghost that could be chased for months while stock grinds toward $380
→ vs conservative: The $4.39 billion unusual item overstates EPS concerns by 8-10% but normalized earnings STILL beat trend by 18-25%, proving the franchise isn't dependent on one-time gains
→ vs conservative: Holding for clean breakout above $368 on 7M shares is classic buying the top; fundamental analysis exists to identify value BEFORE the market recognizes it, not after confirmation
→ vs neutral: Waiting until Q3 earnings in mid-October costs 18 points per share (5% move from $363 to $381 over eight weeks), which is performance drag, not patience
→ vs neutral: The HOLD recommendation is a missed opportunity; best-in-class fundamentals, constructive macro, loaded deal pipeline, and consolidating chart is a setup for adding, not waiting
→ vs conservative: Macro setup is unambiguously bullish with 8% recession probability and fading inflation tail risk; bond rout actually HELPS JPM by widening NIM even as it pressures equity multiples
| $6.09 |
| neutral |
| VWMA(20) | $358.14 | bullish |
| Price Close (Aug 18) | $363.25 | bullish |
| Daily Volume | 4.08M | neutral |
| Aug 12 Swing High | $365.18 | neutral |
Support: 360.48 · 356.63 · 351.79 · 345.32 · 340.87 · 313.12 | Resistance: 367.94 · 365.18
JPM is in a strong medium- and long-term uptrend with price ($363.25) trading comfortably above the 50 SMA ($340.87), 200 SMA ($313.12), and 10 EMA ($360.48). Short-term momentum has cooled modestly (RSI 64.45, MACD histogram -0.36) after pushing the upper Bollinger Band at $367.94, but the structural trend remains intact. The recent rally off the mid-May base (~$292) has lifted price by roughly 24% over three months. Support levels are layered at $360.48 (10 EMA), $356.63 (Bollinger middle), and $340.87 (50 SMA major support), while immediate resistance sits at $365.18 (Aug 12 swing high) and $367.94 (Bollinger upper band). The ATR of $6.09 suggests stop-loss placement $6–$9 below the closing price. The overall bias remains bullish; the trend is intact until a sustained close below the 50 SMA at $340.87.
Market Cap
$965.59 B
P/E (TTM)
15.56x
Forward P/E
14.53x
PEG Ratio
1.77
Price / Book
2.73x
EPS (TTM)
$23.35
Forward EPS
$25.01
Beta
0.977
52-Week High
$366.50
52-Week Low
$279.10
50-Day Moving Avg
$340.38
200-Day Moving Avg
$315.13
Profit Margin
34.9%
Operating Margin
50.4%
Return on Equity (ROE)
17.8%
Return on Assets (ROA)
1.36%
Effective Tax Rate
23.1%
Total Assets
$5,015 B
Total Assets (2025)
$4,424.9 B
Total Assets (2024)
$4,002.8 B
Total Assets (2023)
$3,875.4 B
Total Assets (2022)
$3,665.7 B
Net Loans
$1,516 B
Net Loans (2025)
$1,467.7 B
Net Loans (2022)
$1,115.9 B
Stockholders' Equity
$374.6 B
Stockholders' Equity (2025)
$362.4 B
Stockholders' Equity (2022)
$292.3 B
Tangible Book Value
$289.3 B
Tangible Book Value (2022)
$204 B
Total Debt
$533 B
Long-Term Debt (2025)
$434.0 B
Long-Term Debt (2022)
$295.9 B
Q2 2026 Revenue
$52.85 B
Q2 2026 Net Income
$21.16 B
Q2 2026 Diluted EPS
$7.70
Q1 2026 Revenue
$49.83 B
Q1 2026 Net Income
$16.49 B
Q1 2026 Diluted EPS
$5.94
Q4 2025 Revenue
$45.80 B
Q4 2025 Net Income
$13.03 B
Q4 2025 Diluted EPS
$4.63
Q3 2025 Revenue
$46.43 B
Q3 2025 Net Income
$14.39 B
Q3 2025 Diluted EPS
$5.07
Q2 2025 Revenue
$44.88 B
Q2 2025 Net Income
$14.99 B
Q2 2025 Diluted EPS
$5.24
Q2 2026 NII
$25.51 B
Q2 2025 NII
$23.21 B
Annual Revenue (2025)
$181,847 M
Annual Revenue (2024)
$169,439 M
Annual Revenue (2023)
$154,952 M
Annual Revenue (2022)
$127,727 M
Annual NII (2025)
$95,443 M
Annual NII (2024)
$92,583 M
Annual NII (2023)
$89,267 M
Annual NII (2022)
$66,710 M
Annual Net Income (2025)
$57,048 M
Annual Net Income (2024)
$58,471 M
Annual Net Income (2023)
$49,552 M
Annual Net Income (2022)
$37,676 M
Annual Diluted EPS (2025)
$20.02
Annual Diluted EPS (2024)
$19.75
Annual Diluted EPS (2023)
$16.23
Annual Diluted EPS (2022)
$12.09
Annual Tax Rate (2025)
21.4%
Annual Tax Rate (2024)
22.1%
Annual Tax Rate (2023)
19.6%
Annual Tax Rate (2022)
18.4%
Revenue Growth YoY
+17.7%
Net Income Growth YoY
+41.2%
NII Growth YoY
+9.9%
Asset Growth (6 months)
+13.3%
Net Loan Growth (6 months)
+3.3%
Revenue CAGR (2022-2025)
~12.4%
Net Income CAGR (2022-2025)
~14.8%
Q2 2026 Dividends Paid
$4.34 B
Q2 2026 Share Repurchases
$8.79 B
Q2 2026 Total Capital Return
~$13.1 B
Unusual/Special Item
$4.39 B
Normalized Q2 2026 Net Income
~$17.78 B
Strengths
Concerns
JPMorgan Chase delivered exceptional Q2 2026 results with $52.85B in revenue and $21.16B net income, though the bottom line was boosted by a $4.39B unusual item; excluding this, normalized earnings of ~$17.78B still reflect strong underlying performance with 47% YoY EPS growth. The bank maintains best-in-class profitability metrics (17.8% ROE, 1.36% ROA, 34.9% profit margin), a robust capital position with CET1 well above regulatory minimums, and continues aggressive capital returns (~($13.1B quarterly). With total assets approaching $5 trillion and a diversified four-segment franchise, JPM remains the premier U.S. mega-cap bank, though the stock trades near its 52-week high with limited valuation cushion and investors should monitor credit quality given rapid loan portfolio expansion.
Macro: Higher-for-longer regime: Polymarket 85% odds of no Fed cuts in 2026; 30-year Treasury yield at 19-year high per MT Newswires/Reuters; long-end yields at multi-decade highs driven by persistent inflation concerns, heavy sovereign issuance, debt sustainability worries, and term premium re-pricing. Mideast conflict fears growing (Reuters) with oil extending gains for a third session. US recession probability 8%, UK recession 12%, Japan recession 31%. Polymarket inflation >4.5% in 2026 at 12% (down 8pp WoW) — disinflation signal but sticky above target. FRED macro data unavailable (no API key configured).